Published on 13 Mar 2022 on Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple...
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) was among the biggest gainers of the week. The stock moved out of penny stock territory after the company announced UnitedHealth Incorporated (NYSE: UNH) added Eysuvis 0.25% as a covered brand on its commercial formularies, effective March 2022.